van den Blink, Bernt <br/><br/>
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.  [electronic resource] 

 -  The European respiratory journal  Mar 2016 
 - 889-97 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1399-3003 
<br/><br/><label>Standard No.: </label>10.1183/13993003.00850-2015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Exercise Test<br/>Female<br/>Homeodomain Proteins--adverse effects<br/>Humans<br/>Idiopathic Pulmonary Fibrosis--drug therapy<br/>Lung--physiopathology<br/>Male<br/>Middle Aged<br/>Netherlands<br/>Recombinant Proteins--adverse effects<br/>Respiratory Function Tests<br/>Serum Amyloid P-Component--adverse effects<br/>Treatment Outcome<br/>United States